Associated response in bone mineral density and atherogenic lipid profile during treatment with two different selective @entity172 receptor modulators: @entity46018 and XXXX .

@entity172 @entity1 @entity79 @entity165 @entity46018 @entity441
OBJECTIVE: We recently demonstrated a correlation between the responses in two target areas, bone and lipids, during treatment with hormone replacement therapy. Whether the same association exists during treatment with selective @entity172 receptor modulators (SERMs) has not been examined before. STUDY DESIGN: This was an exploratory, post hoc analysis of data from two randomized, double-blind, placebo-controlled trials. STUDY POPULATION: From both studies we examined only the Danish subpopulation. Study 1 included 133 @entity1 treated with placebo or @entity46018 in four different doses for 12 months, and study 2 included 248 @entity1 treated with @entity441 in three different doses or placebo for 24 months. MEASUREMENTS: @entity79 ( @entity79 ) of the spine and hip was measured semiannually. Serum lipids and biochemical bone markers were determined at each visit. To eliminate interindividual differences, all values were calculated as individual percentage change from baseline. RESULTS: We found a significant correlation between the increase in @entity79 of the spine and hip and the decrease in total @entity165 and low-density lipoprotein. CONCLUSION: Our study showed that, in healthy postmenopausal @entity1 , the @entity1 with the greatest response in @entity79 were also those with the most favorable response in lipid profile during treatment with SERMs.
